Expect significant downward pressure from the massive resale registration. The 16.45M shares registered exceed the current float, and selling stockholders (including a board member) can sell at any time after the S-3 becomes effective. Watch for stockholder approval on June 17, 2026 — if denied, Dr. Bailey's 11.8M shares remain restricted. Monitor for 424B prospectus supplements indicating actual selling begins. The company's cash burn at $6.9M/quarter suggests ~3.5 quarters of runway — further dilution via the redeemable warrants ($5 strike, deeply out of the money) is unlikely, putting pressure on the stock.
Price Chart
Executive Summary
Serina Therapeutics filed an S-3 registration statement to register up to 16,450,442 shares of common stock for resale by selling stockholders, including insider Dr. Gregory H. Bailey. The shares stem from a $21.2M March/April 2026 PIPE, including PIPE shares, pre-funded/redeemable warrants, and Series A conversion shares. With 14,997,505 shares currently outstanding, potential dilution exceeds 100%. The company disclosed substantial doubt about its ability to continue as a going concern in its recent 10-Q (net loss -$6.9M in Q1 2026 vs -$4.8M in Q1 2025), making this a desperation raise registration that enables selling shareholders to exit.
Key Facts
- Up to 16,450,442 shares registered for resale vs. 14,997,505 currently outstanding — more than 100% potential dilution
- $21.2M March 2026 PIPE priced at $2.25/share vs. current stock price of $1.61 (premium had eroded by filing date)
- Pre-Funded Warrants exercisable at $0.0001/share; Redeemable Warrants exercisable at $5.00/share
- Q1 2026 net loss of -$6.9M (-$0.58 EPS) deepened from -$4.8M (-$0.49 EPS) in Q1 2025
- Cash of $24.5M as of Q1 2026, plus $5.2M in April 2026; company still pre-revenue clinical-stage
- Going concern warning in most recent 10-K (March 25, 2026) — substantial doubt about continued viability
- NYSE American non-compliance notice received January 9, 2026; compliance plan accepted but subject to ongoing review
- Board member/Co-Chair Dr. Gregory H. Bailey is largest selling stockholder, offering up to 11,830,472 shares (72% of registered shares)
Financial Impact
Potential overhang of $25.8M at May 19 closing price of $1.57/share; $21.2M gross proceeds already raised in PIPE; net loss deepened 44% YoY to -$6.9M
Risk Factors
- Massive overhang from 16.45M registered shares vs 15.0M outstanding — selling pressure could crush stock price
- Going concern risk — company has no revenue, deepening losses, and a going concern warning
- NYSE American delisting risk — company received non-compliance notice in January 2026
- Insider selling by Co-Chair Dr. Bailey (11.8M shares) signals potential lack of confidence
- Series A preferred holders forced to convert at $2.25 vs original $5.18, creating selling pressure from holders looking to exit
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001493152-26-025007 |
| Exhibit: ex107.htm | 0001493152-26-025007 |
| Exhibit: ex5-1.htm | 0001493152-26-025007 |
| Exhibit: ex23-1.htm | 0001493152-26-025007 |
| Document: 0001493152-26-025007-index-headers.html | 0001493152-26-025007 |
| Document: 0001493152-26-025007-index.html | 0001493152-26-025007 |
| Document: 0001493152-26-025007.txt | 0001493152-26-025007 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 6w ago | 8-K | $2.57 $2.16 | ▼ −15.95% | ▼ −14.86% | $1.77 (−31.13%) |
Jul 23, 2026 13w ago | Press Release | $2.09 $2.04 | ▼ −2.39% | ▼ −2.87% | $1.77 (−15.31%) |
Jul 22, 2026 13w ago | 8-K | $2.09 $2.04 | ▼ −2.39% | ▼ −2.87% | $1.77 (−15.31%) |
Jun 4, 2026 20w ago | EFFECT | $1.86 $1.81 | ▲ +2.69% | ▲ +0.14% | $1.77 (+4.84%) |
May 26, 2026 21w ago | Insider Cluster | $1.80 $1.79 | ▼ −0.56% | ▼ −1.02% | $1.77 (−1.67%) |
May 26, 2026 21w ago | Insider Cluster | $1.80 $1.79 | ▲ +0.56% | ▲ +1.02% | $1.77 (+1.67%) |
May 22, 2026 22w ago | S-3 | $1.92 $1.81 | ▲ +5.73% | ▲ +6.81% | $1.77 (+7.81%) |
Mar 27, 2026 30w ago | 10-K/A | $2.27 $2.15 | ▼ −5.29% | ▼ −9.15% | $1.77 (−22.03%) |
Mar 25, 2026 30w ago | Press Release | $2.61 $2.12 | ▼ −18.77% | ▼ −20.41% | $1.77 (−32.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers